David I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) General Counsel David I. Sandoval sold 4,466 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $4.54, for a total value of $20,275.64. Following the transaction, the general counsel now directly owns 41,447 shares in the company, valued at $188,169.38. The trade was a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

MaxCyte Stock Down 5.5 %

Shares of MXCT traded down $0.27 during trading hours on Tuesday, reaching $4.64. The company’s stock had a trading volume of 1,018,515 shares, compared to its average volume of 661,274. The firm has a market cap of $490.50 million, a price-to-earnings ratio of -13.65 and a beta of 1.29. The company has a 50 day moving average of $3.92 and a two-hundred day moving average of $4.02. MaxCyte, Inc. has a 1-year low of $3.16 and a 1-year high of $5.32.

MaxCyte (NASDAQ:MXCT) last released its earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The company had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. During the same quarter in the prior year, the firm earned ($0.11) EPS. As a group, analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MXCT. Franklin Resources Inc. acquired a new stake in MaxCyte in the 3rd quarter worth approximately $260,000. Geode Capital Management LLC raised its holdings in MaxCyte by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after acquiring an additional 47,960 shares during the period. Barclays PLC lifted its position in MaxCyte by 329.3% during the 3rd quarter. Barclays PLC now owns 165,765 shares of the company’s stock worth $645,000 after acquiring an additional 127,156 shares during the last quarter. Mudita Advisors LLP boosted its holdings in MaxCyte by 5.6% during the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock valued at $12,267,000 after acquiring an additional 167,101 shares during the period. Finally, State Street Corp grew its position in shares of MaxCyte by 5.1% in the third quarter. State Street Corp now owns 2,269,135 shares of the company’s stock valued at $8,827,000 after purchasing an additional 111,066 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.